Search

Your search keyword '"Courbon, F"' showing total 315 results
Start Over Author "Courbon, F"
315 results on '"Courbon, F"'

14. L’index basé sur l’inflammation et l’hétérogénéité tumorale en TEP-TDM au 68Ga DOTATOC : prédictifs de l’efficacité d’une thérapie par Lu 177-oxodotréotide des tumeurs neuroendocrines

Author

Vija, L., primary, Dierickx, L., additional, Kanoun, S., additional, Texier, J.S., additional, Terroir, M., additional, Gabiache, E., additional, Zerdoud, S., additional, Brillouet, S., additional, Vallot, D., additional, and Courbon, F., additional

Published
2023
Full Text
View/download PDF

20. Efficacité et tolérance du Lu-DOTATATE chez les patients atteints de TNE pancréatiques avancées : analyse rétrospective de la cohorte internationale NETTER-R

Author

Courbon, F., primary, Clement, D., additional, Navalkissoor, S., additional, Srirajaskanthan, R., additional, Dierickx, L., additional, Eccles, A., additional, Lewington, V., additional, Mitjavila, M., additional, Percovich, J.C., additional, He, B., additional, Hertelendi, M., additional, and Ramage, J., additional

Published
2022
Full Text
View/download PDF

21. Caractérisation des patients progressifs pendant la lutathérapie

Author

Molina, O., primary, Hindié, E., additional, Tlili, G., additional, Terrebonne, E., additional, Smith, D., additional, Gaye, D., additional, Tabarin, A., additional, Hadoux, J., additional, Walter, T., additional, Deshayes, E., additional, Courbon, F., additional, Dierickx, L., additional, Duval, M., additional, Hentic, O., additional, Laboureau, S., additional, Lacombe, M., additional, Jannin, A., additional, Do Cao, C., additional, Hautefeuille, V., additional, Taïeb, D., additional, Thuillier, P., additional, and Haissaguerre, M., additional

Published
2021
Full Text
View/download PDF

22. Liste des collaborateurs

Author

Alberini, J.-L., primary, Ammari, S., additional, Balleyguier, C., additional, Barthélémy, P., additional, Belhadj, K., additional, Benyoucef, A., additional, Bidault, F., additional, Bonardel, G., additional, Cazals, X., additional, Chalaye, J., additional, Chapet, S., additional, Chevalier, A., additional, Chevalier, D., additional, Cottier, J.-P., additional, Courbon, F., additional, Daly-Schveitzer, N., additional, De Bazelaire, C., additional, De Kerviler, E., additional, Delanian, S., additional, Destrieux, C., additional, Dubray, B., additional, Dubrulle, F., additional, Fakhry, N., additional, Feydy, A., additional, Ghouti, L., additional, Giraud, P., additional, Groheux, D., additional, Haie-Meder, C., additional, Herin, E., additional, Itti, E., additional, Jausset, F., additional, Kolesnikov-Gauthier, H., additional, Koning, E., additional, Kraeber-Bodéré, F., additional, Lagrange, J.-L., additional, Langer, A., additional, Laurent, F., additional, Laurent, V., additional, Lauvin, M.-A., additional, Leblanc, E., additional, Legou, F., additional, Luciani, A., additional, Michaud, L., additional, Oldrini, G., additional, Oliver, A., additional, Olivier, P., additional, Paycha, F., additional, Peiffert, D., additional, Pernin, M., additional, Pointreau, Y., additional, Quéro, L., additional, Rahmouni, A., additional, Raimbault, A., additional, Renard-Penna, R., additional, Reyre, A., additional, Ribeiro, M., additional, Rousseau, C., additional, Roy, C., additional, Rust, E., additional, Savoye-Collet, C., additional, Simon, J.-M., additional, Souillard-Scemama, R., additional, Taïeb, S., additional, Thureau, S., additional, Varoquaux, A., additional, Vera, P., additional, and Wong-Hee-Kam, S., additional

Published
2014
Full Text
View/download PDF

25. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

Author

Strosberg, J.R. (Jonathan), Kunz, P.L. (Pamela L.), Hendifar, A. (Andrew), Yao, J. (James), Bushnell, D. (David), Kulke, M. (Matthew), Baüm, R.P. (Richard), Caplin, M. (Martyn), Ruszniewski, P. (Philippe), Delpassand, E. (Ebrahim), Hobday, T. (Timothy), Verslype, C. (Chris), Benson, A. (Al), Srirajaskanthan, R. (Rajaventhan), Pavel, M. (Marianne), Mora, J. (Jaume), Berlin, J. (Jordan), Grande, E. (Enrique), Reed, N. (Nicholas), Seregni, E. (Ettore), Paganelli, G. (Giovanni), Severi, S., Morse, M. (Michael), Metz, D.C. (David C.), Ansquer, C. (Catherine), Courbon, F. (Frédéric), Al-Nahhas, A. (Adil), Baudin, E. (Eric), Giammarile, F. (Francesco), Taïeb, A., Mittra, E. (Erik), Wolin, E.M. (Edward), O’Dorisio, T.M. (Thomas M.), Lebtahi, R. (Rachida), Deroose, C.M. (Christophe M.), Grana, C.M. (Chiara M.), Bodei, L. (Lisa), Öberg, K. (Kjell), Polack, B.D. (Berna Degirmenci), He, B. (Beilei), Mariani, M.F. (Maurizio F.), Gericke, G. (Germo), Santoro, P. (Paola), Erion, J.L. (Jack), Ravasi, L. (Laura), Krenning, E.P. (Eric), Strosberg, J.R. (Jonathan), Kunz, P.L. (Pamela L.), Hendifar, A. (Andrew), Yao, J. (James), Bushnell, D. (David), Kulke, M. (Matthew), Baüm, R.P. (Richard), Caplin, M. (Martyn), Ruszniewski, P. (Philippe), Delpassand, E. (Ebrahim), Hobday, T. (Timothy), Verslype, C. (Chris), Benson, A. (Al), Srirajaskanthan, R. (Rajaventhan), Pavel, M. (Marianne), Mora, J. (Jaume), Berlin, J. (Jordan), Grande, E. (Enrique), Reed, N. (Nicholas), Seregni, E. (Ettore), Paganelli, G. (Giovanni), Severi, S., Morse, M. (Michael), Metz, D.C. (David C.), Ansquer, C. (Catherine), Courbon, F. (Frédéric), Al-Nahhas, A. (Adil), Baudin, E. (Eric), Giammarile, F. (Francesco), Taïeb, A., Mittra, E. (Erik), Wolin, E.M. (Edward), O’Dorisio, T.M. (Thomas M.), Lebtahi, R. (Rachida), Deroose, C.M. (Christophe M.), Grana, C.M. (Chiara M.), Bodei, L. (Lisa), Öberg, K. (Kjell), Polack, B.D. (Berna Degirmenci), He, B. (Beilei), Mariani, M.F. (Maurizio F.), Gericke, G. (Germo), Santoro, P. (Paola), Erion, J.L. (Jack), Ravasi, L. (Laura), and Krenning, E.P. (Eric)

Abstract

Purpose: To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate. Methods: In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. Results: Significantly prolonged median PFS occurred with 177Lu-Dotatate versus octreotide LAR 60 mg in patients with low (< 25%), moderate (25–50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177Lu-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. Conclusions: 177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov: NCT01578239, EudraCT: 2011-005049-11.

Published
2020
Full Text
View/download PDF

26. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

Author

Strosberg, J, Kunz, PL, Hendifar, A, Yao, J, Bushnell, D, Kulke, MH, Baum, RP, Caplin, M, Ruszniewski, P, Delpassand, E, Hobday, T, Verslype, C, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Paganelli, G, Severi, S, Morse, M, Metz, DC, Ansquer, C, Courbon, F, Al-Nahhas, A, Baudin, E, Giammarile, F, Taïeb, D, Mittra, E, Wolin, E, O’Dorisio, TM, Lebtahi, R, Deroose, CM, Grana, CM, Bodei, L, Öberg, K, Polack, BD, He, B, Mariani, MF, Gericke, G, Santoro, P, Erion, JL, Ravasi, L, Krenning, Eric, Strosberg, J, Kunz, PL, Hendifar, A, Yao, J, Bushnell, D, Kulke, MH, Baum, RP, Caplin, M, Ruszniewski, P, Delpassand, E, Hobday, T, Verslype, C, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Paganelli, G, Severi, S, Morse, M, Metz, DC, Ansquer, C, Courbon, F, Al-Nahhas, A, Baudin, E, Giammarile, F, Taïeb, D, Mittra, E, Wolin, E, O’Dorisio, TM, Lebtahi, R, Deroose, CM, Grana, CM, Bodei, L, Öberg, K, Polack, BD, He, B, Mariani, MF, Gericke, G, Santoro, P, Erion, JL, Ravasi, L, and Krenning, Eric

Published
2020

29. Diagnosis and Treatment of Insulinomas in the Adults

Author

Vezzosi, D., primary, Bennet, A., additional, Maiza, J.C., additional, Buffet, A., additional, Grunenwald, S., additional, Fauvel, J., additional, Courbon, F., additional, Otal, P., additional, Carrere, N., additional, and Caro, Ph., additional

Published
2011
Full Text
View/download PDF

36. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Author

Strosberg, J, El Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, Pl, Kulke, Mh, Jacene, H, Bushnell, D, O'Dorisio, Tm, Baum, Rp, Kulkarni, Hr, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, Jl, Ruszniewski, P, Kwekkeboom, D, Krenning, E, Ansquer, C, Baudin, E, Courbon, F, Giammarile, F, Taieb, D, Scheidhauer, K, Weber, M, Bodei, L, Brianzoni, E, DELLE FAVE, Gianfranco, Chiara Grana, M, Mariani, G, Rindi, G, Severi, S, Azevedo, I, Sundin, A, Al‐nahhas, A, Freemantle, N, Grossman, A, Manoharan, P, Anthony, L, Benson, Ab, Garbus, S, Kulke, M, Kvols, L, Metz, D, Morse, M, Schipper, M, Yao, J., and Radiology & Nuclear Medicine

Subjects
Male, medicine.medical_specialty, Octreotide, Antineoplastic Agents, Kaplan-Meier Estimate, Neuroendocrine tumors, Gastroenterology, Disease-Free Survival, Drug Administration Schedule, 030218 nuclear medicine & medical imaging, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Organometallic Compounds, medicine, Clinical endpoint, Humans, Infusions, Intravenous, Telotristat ethyl, Aged, Gastrointestinal Neoplasms, Tumors, DOTA-TATE, Intestins, business.industry, Nausea, General Medicine, receptor radionuclide therapy, radiolabeled somatostatin analog, carcinoid-syndrome, prognostic-factors, survival, prrt, lu-177-dota-octreotate, lu-177-octreotate, scintigraphy, octreotide, Middle Aged, medicine.disease, Surgery, Intestines, Clinical trial, Neuroendocrine Tumors, chemistry, Delayed-Action Preparations, 030220 oncology & carcinogenesis, Radionuclide therapy, Female, business, medicine.drug
Abstract

Background: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 ((177)Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. Methods: We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) ((177)Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here. Results: At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the (177)Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the (177)Lu-Dotatate group versus 3% in the control group (PConclusions: Treatment with (177)Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the (177)Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11 .).

Published
2017

39. Tumour Growth Rate (TGR) to Monitor Growth/Predict Response to Lanreotide Autogel (LAN) Use before, during and after Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs): Data from PRELUDE

Author

Prasad, V, Srirajaskanthan, R., Grana, C. M., Baldari, S., Shah, T., Lamarca, A., Courbon, F., Scheidhauer, K., Baudin, E., Thanh Truong, X. M., Houchard, A., and Bodei, L.

Subjects
peptide receptor radionuclide therapy, objective response, lanreotide autogel, neuroendocrine tumours, tumour growth rate
Published
2019

44. Automating de-identification and sharing DICOMs with a free and open-source software

Author

UCL - SST/ICTM/INGI - Pôle en ingénierie informatique, Vongsalat, A., Kanoun, S., Berriolo-Riedinger, A., Humbert, O., Jodogne, Sébastien, Lambrechts, F., Vallot, D., Pascal, P., Tal, I., Berry, I., Courbon, F., UCL - SST/ICTM/INGI - Pôle en ingénierie informatique, Vongsalat, A., Kanoun, S., Berriolo-Riedinger, A., Humbert, O., Jodogne, Sébastien, Lambrechts, F., Vallot, D., Pascal, P., Tal, I., Berry, I., and Courbon, F.

Published
2018

45. Automating DICOM retrieve from PACS with free and open-source software

Author

UCL - SST/ICTM/INGI - Pôle en ingénierie informatique, Kanoun, S., Silva, Y.E., Vongsalat, A., Jodogne, Sébastien, Lambrechts, F., Berriolo-Riedinger, A., Caselles, O., Tal, I., Berry, I., Courbon, F., UCL - SST/ICTM/INGI - Pôle en ingénierie informatique, Kanoun, S., Silva, Y.E., Vongsalat, A., Jodogne, Sébastien, Lambrechts, F., Berriolo-Riedinger, A., Caselles, O., Tal, I., Berry, I., and Courbon, F.

Published
2018

46. Reverse Engineering Flash EEPROM Memories Using Scanning Electron Microscopy

Author

Courbon, F, Skorobogatov, S, and Woods, C

Subjects
reverse engineering, Scanning Electron Microscope (SEM), Passive Voltage Contrast (PVC), 010302 applied physics, 0103 physical sciences, 0202 electrical engineering, electronic engineering, information engineering, 020201 artificial intelligence & image processing, 02 engineering and technology, 021001 nanoscience & nanotechnology, 0210 nano-technology, Flash EEPROM, 01 natural sciences, 020202 computer hardware & architecture
Abstract

In this article, a methodology to extract Flash EEPROM memory contents is presented. Samples are first backside prepared to expose the tunnel oxide of floating gate transistors. Then, a Scanning Electron Microscope (SEM) in the so called Passive Voltage Contrast (PVC) mode allows distinguishing ‘0’ and ‘1’ bit values stored in individual memory cell. Using SEM operator-free acquisition and standard image processing technique we demonstrate the possible automating of such technique over a full memory. The presented fast, efficient and low cost technique is successfully implemented on 0.35$\mu \textit{m}$ technology node microcontrollers and on a 0.21$\mu \textit{m}$ smart card type integrated circuit. The technique is at least two orders of magnitude faster than state-of-the-art Scanning Probe Microscopy (SPM) methods. Without adequate protection an adversary could obtain the full memory array content within minutes. The technique is a first step for reverse engineering secure embedded systems.

Published
2017

48. Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)

Author

Prasad, V., primary, Srirajaskanthan, R., additional, Grana, C.M., additional, Baldari, S., additional, Shah, T., additional, Lamarca, A., additional, Courbon, F., additional, Scheidhauer, K., additional, Baudin, E., additional, Truong-Thanh, X.-M., additional, Houchard, A., additional, and Bodei, L., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results